Millipore Sigma Vibrant Logo

SCC126 SF7761 Human DIPG H3.3-K27M Cell Line

SF7761 pediatric diffuse intrinsic pontine glioma (DIPG) cell line harbors the histone H3.3 Lys 27-to-methionine (K27M) mutation and can support research and drug development efforts targeting DIPG.

SF7761 Human DIPG H3.3-K27M Cell Line: SDB (Sicherheitsdatenblätter), Analysenzertifikate und Qualitätszertifikate, Dossiers, Broschüren und andere verfügbare Dokumente.
Key Applications: Cell Culture
View Products on Sigmaaldrich.com
SCC126
≥ 200 neurospheres/vial   
Preis wird abgerufen...
Preis nicht abrufbar
Die Mindestmenge muss ein Vielfaches sein von
Maximum Quantity is
Bei Bestätigung Weitere Informationen
Sie haben () gespart
 
—
Bitte erfragen
—
Eingeschränkte Verfügbarkeit Eingeschränkte Verfügbarkeit
Lieferbar 
Produkt wurde eingestellt
Begrenzter Lagerbestand
Bestätigung der Verfügbarkeit erforderlich
    Restmenge: Angebot folgt
      Restmenge: Angebot folgt
      Bitte erfragen
      Kontakt zum Kundenservice
      Contact Customer Service

       

      Kontakt zum Kundenservice

      Übersicht

      Replacement Information

      Key Spec Table

      Key Applications
      CULT
      Description
      Catalogue NumberSCC126
      DescriptionSF7761 Human DIPG H3.3-K27M Cell Line
      OverviewSF7761 is a human glioma cell line derived by surgical biopsy from a young female H3.3K27M DIPG patient (5). The tumor cells were immortalized with hTERT (human telomerase ribonucleoprotein reverse transcriptase) using retroviral transduction. SF7761 cells are tumorigenic in athymic rodents with the tumor cells recapitulating the infiltrative growth of human brainstem gliomas (5, 6).

      IMPORTANT NOTE: SF7761 are grown as neurospheres in suspension culture. Neurospheres are to be passaged using gentle mechanical trituration when they reach diameters of 200-500 um or through enzymatic dissociation.
      Background InformationDiffuse intrinsic pontine gliomas (DIPG) are highly aggressive and difficult to treat tumors arising in the ventral pons of the brain stem. Despite therapeutic advances, DIPG is incurable and most patients, primarily children, die within 2 years of diagnosis. DIPG is one of the leading causes of death in children with brain tumors (1).

      A somatic mutation of histone H3.3 resulting in a lysine 27 to methionine substitution (H3.3K27M) occurs in 60% of DIPG (2). In H3.3K27M DIPG patient samples, levels of H3K27 dimethylation (H3K27me2) and trimethylation (H3K27me3) are reduced globally. Expression of H3.3K27M was also shown to be associated with increased levels of H3K27 acetylation (H3K27ac) and recruitment of bromodomain proteins at sites of active transcription (4). These epigenetic changes are thought to be important factors driving DIPG oncogenesis (2,3)

      References
      1. Schroeder KM et al. (2014) Pediatr. Res. 75(1-2): 205–209.
      2. Lewis PW et al. (2013) Science 340(6134): 857–861.
      3. Chan KM et al. (2013) Genes & Development 27(9): 985-990.
      4. Piunti A et al. (2017) Nat. Med. 23(4): 493-500.
      5. Hashizume R et al. (2012) Neuro Oncol. 110(3): 305-13.
      6. Hashizume R et al. (2014) Nat Med 20(12): 1394-6.
      References
      Product Information
      Quality LevelMQ100
      Applications
      ApplicationSF7761 pediatric diffuse intrinsic pontine glioma (DIPG) cell line harbors the histone H3.3 Lys 27-to-methionine (K27M) mutation and can support research and drug development efforts targeting DIPG.
      Key Applications
      • Cell Culture
      Application NotesThis product is intended for sale and sold solely to academic institutions for internal academic research use per the terms of the “Academic Use Agreement” as detailed in the product documentation. For information regarding any other use, please contact licensing@emdmillipore.com.
      Biological Information
      Cell Line Type
      • Cancer Cells
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality Assurance• Each vial contains ≥ 200 viable neurospheres.
      • Cells are tested negative for HPV-16, HPV-18, Hepatitis A, C, Herpesvirus type 6, 7, 8 and HIV-1 & 2 viruses by PCR.
      • Cells are negative for mycoplasma contamination.
      • Each lot of cells is genotyped by STR analysis to verify the unique identity of the cell line.
      Usage Statement
      • This product contains genetically modified organisms (GMO). Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively. This legislation obliges Merck to request certain information about you and the establishment where the GMOs are being handled. Click here for Enduser Declaration (EUD) Form.
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsStore in liquid nitrogen. The cells can be cultured for at least 10 passages after initial thawing without significantly affecting the cell marker expression and functionality.
      Packaging Information
      Material Size≥ 200 neurospheres/vial
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Bestellnummer GTIN
      SCC126 04054839354779